Norethindrone acetate and estradiol-induced endometrial hyperplasia
| Autor: | Dean L. Moyer, Nayan Nanavati, Joan-Carles Arce, Robert J. Kurman, David F Archer, Juan C. Felix |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
Norethisterone medicine.drug_class medicine.medical_treatment Urology Endometrium Drug Administration Schedule Double-Blind Method Internal medicine medicine Humans Climacteric Chemotherapy Dose-Response Relationship Drug Estradiol business.industry Estrogen Replacement Therapy Obstetrics and Gynecology Norethindrone Acetate Middle Aged Hyperplasia medicine.disease Endometrial hyperplasia Dose–response relationship medicine.anatomical_structure Endocrinology Estrogen Endometrial Hyperplasia Drug Therapy Combination Female Norethindrone business medicine.drug |
| Zdroj: | Obstetrics & Gynecology. 96:373-379 |
| ISSN: | 0029-7844 |
| DOI: | 10.1016/s0029-7844(00)00944-3 |
| Popis: | To identify the lowest effective continuous dose of norethindrone acetate that significantly reduces 12-month incidence of endometrial hyperplasia associated with unopposed 17beta-estradiol (E2), 1 mg.In a double-masked, randomized, multicenter study, 1176 healthy postmenopausal women 45 years of age or older without evidence of endometrial abnormalities were given 12 months of treatment with unopposed E2, 1 mg, or continuous-combined regimens of E2, 1 mg, and norethindrone acetate, 0.1 mg, 0.25 mg, or 0.5 mg. Endometrial histology was evaluated at the end of the treatment period.Continuous-combined E2-norethindrone acetate regimens significantly reduced 12-month incidence of endometrial hyperplasia compared with unopposed E2 1 mg (P.001). Endometrial hyperplasia occurred in 14.6% of women treated with unopposed E2 1 mg, whereas in all continuous-combined groups, the rate decreased to less than 1%. Among patients who received E2-norethindrone acetate 0.1 mg, incidence was 0.8%; among those who received 0.25 mg and 0.5 mg, it was 0.4%.Continuous norethindrone acetate at doses as low as 0.1 mg combined with E2 1 mg effectively negated risk for endometrial hyperplasia associated with unopposed E2 1 mg, at least for the first year of therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|